Drug Profile
DA 1241
Alternative Names: DA-1241Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Dong-A ST
- Developer Dong-A ST; NeuroBo Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 18 Jan 2024 Adverse events data from a preclinical study released by NeuroBo Pharmaceuticals
- 14 Sep 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT06054815)
- 02 May 2023 NeuroBo Pharmaceuticals plans a phase IIa trial for Non-alcoholic steatohepatitis (PO) and Type 2 diabetes mellitus in Q3 of 2023